Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-02 Other antispasmodics
Links
Biosimilars policy statement- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Glycopyrronium Oral NMR
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Dec 2017: Eluxadoline (Truberzi): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA: Domperidone: risks of cardiac side effects
- MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA: Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease
- MHRA: Metoclopramide: risk of neurological adverse effects
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
- NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea